Skip to main content

The Wistar Institute

|

Novel DNA-based Immunotherapy for Neutralizing Hepatitis B Virus infection

PHILADELPHIA — (May. 28, 2020) — Scientists at The Wistar Institute developed a synthetic DNA approach that instructs in vivo production of a human monoclonal antibody able to neutralize hepatitis B virus (HBV) and prevent infection of liver cells i…
|

Positive Results from Preclinical Testing Support Clinical Development of COVID-19 DNA Vaccine

PHILADELPHIA — (May 20, 2020) — The Wistar Institute, an international biomedical research leader in cancer, immunology and infectious disease, announces a study reporting initial immunogenicity of a synthetic DNA vaccine for SARS-CoV-2 developed in…
|

Philanthropy Powering Science: $1.6M in New Funding for Wistar Coronavirus Research

In mere weeks, philanthropic support of Wistar’s Coronavirus Discovery Fund has exceeded $1.6M in new funding thanks to an extraordinary response from individuals, foundations, and corporate sponsors. As our scientists focused their resear…
|

Spotlight on Wistar COVID-19 Researcher: Hildegund C.J. Ertl, M.D. 

Dr. Ertl is a global leader in Wistar’s Vaccine & Immunotherapy Center whose research focuses on preventing rabies, HBV, HIV, HPV, influenza, and other deadly viruses using innovative patented technologies. In response to the global COVID-19 eme…
|

#Funding4Cure 2020: Supporting Cancer Research Virtually During the Pandemic

The Pennsylvania Cancer Alliance, a coalition of the state’s leading cancer research institutions, meets every year in early May for a lobbying initiative to engage legislators and spotlight the impact the Commonwealth Universal Research Enhancement…
|

The Wistar Institute Appoints Bin Tian, Ph.D., as Professor in the Cancer Center and Co-director of the Center for Systems & Computational Biology

PHILADELPHIA — (May, 1, 2020) — The Wistar Institute, an international biomedical research leader in cancer, immunology and infectious diseases, announces the appointment of molecular systems biologist Bin Tian, Ph.D., as professor in the Cancer Cen…
|

The Wistar Institute and Batavia Biosciences Launch Collaboration to Manufacture and Distribute Wistar’s Rubella Vaccine Globally

PHILADELPHIA — (April 29, 2020) — The Wistar Institute and Batavia Biosciences announce the launch of a strategic collaboration aimed to streamline the clinical grade manufacture and global distribution of Wistar’s rubella vaccine seed stock commonl…
|

Uncertain Times: Wistar’s Historic Strides in the Time of COVID-19

This is week six of the stay-at-home order in Pennsylvania and Darien Sutton, associate director of Communications & Marketing, caught up again with President and CEO Dario C. Altieri, M.D., for their second virtual chat about what’s going on wi…
|

Spotlight on Wistar COVID-19 Researchers: Luis Montaner, D.V.M., D.Phil., & Joseph Salvino, Ph.D.

Dr. Luis Montaner is an HIV expert focused on finding new ways to boost the natural function of the immune system to combat infection or viral-associated disease. Dr. Joseph Salvino is a medicinal chemist and an expert in drug discovery and identifi…
|

Spotlight on Wistar COVID-19 Researcher: Daniel Kulp, Ph.D., Associate Professor 

Principal investigator Dr. Daniel Kulp is one of a group of Wistar scientists undertaking coronavirus research in response to the pandemic. A protein engineering expert, his lab focuses on rational vaccine and therapeutic antibody design for a varie…